

Stahl's Essential Psychopharmacology

Prescriber's Guide

SEVENTH EDITION

With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this very latest edition of what has become the indispensable formulary in psychopharmacology.

This new edition features several new compounds as well as information about new formulations, new indications, and new warnings for existing drugs.

With its easy-to-use, template-driven navigation system, the *Prescriber's Guide* combines evidence-based data with clinically informed advice to support everyone prescribing in the field of mental health.

Stephen M. Stahl is Professor of Psychiatry and Neuroscience at the University of California, Riverside and San Diego and Honorary Visiting Senior Fellow in Psychiatry at the University of Cambridge, UK. He has conducted various research projects awarded by the National Institute of Mental Health, Veterans Affairs, and the pharmaceutical industry. Author of more than 500 articles and chapters, Dr Stahl is also the author of the bestseller *Stahl's Essential Psychopharmacology*.



Stahl's Essential Psychopharmacology

Prescriber's
Guide
SEVENTH EDITION

Stephen M. Stahl

University of California at Riverside and at San Diego, Riverside and San Diego, California

Editorial assistant Meghan M. Grady

With illustrations by Nancy Muntner





CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

One Liberty Plaza, 20th Floor, New York, NY 10006, USA

477 Williamstown Road, Port Melbourne, VIC 3207, Australia

314-321, 3rd Floor, Plot 3, Splendor Forum, asola District Centre, New Delhi - 110025, India

79 Anson Road, #06-04/06, Singapore 079906

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781316618134

© Stephen M. Stahl 2005, 2006, 2009, 2011, 2014, 2017, 2021

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2005

Revised and updated edition published 2006

Third edition published 2009

Fourth edition published 2011

Fifth edition published 2014

Sixth edition published 2017

Seventh edition published 2021

Printed in the United Kingdom by TJ Books Ltd, Padstow Cornwall

A catalog record for this publication is available from the British Library.

ISBN 978-1-108-92601-0 Paperback ISBN 978-1-108-92602-7 Spiral

Additional resources for this publication at www.stahlonline.org

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party Internet Web sites referred to in this publication, and does not guarantee that any content on such Web sites is, or will remain, accurate or appropriate.



Contents

	Introduction	xi
	List of icons	XV
1	acamprosate	1
2	agomelatine	5
3	alprazolam	11
4	amisulpride	17
5	amitriptyline	25
6	amoxapine	33
7	amphetamine (d)	39
8	amphetamine (d,l)	45
9	aripiprazole	53
10	armodafinil	65
11	asenapine	71
12	atomoxetine	79
13	benztropine	85
14	blonanserin	89
15	bremelanotide	95
16	brexanolone	99
17	brexpiprazole	103
18	buprenorphine	111
19	bupropion	117
20	buspirone	123
21	caprylidene	127
22	carbamazepine	131
23	cariprazine	137
24	chlordiazepoxide	147
25	chlorpromazine	153
26	citalopram	159
27	clomipramine	165
28	clonazepam	173
29	clonidine	179
30	clorazepate	185
31	clozapine	191
32	cyamemazine	201
33	desipramine	207



34	desvenlafaxine	215
35	deutetrabenazine	221
36	dextromethorphan	225
37	diazepam	229
38	diphenhydramine	235
39	disulfiram	239
40	donepezil	243
41	dothiepin	249
42	doxepin	255
43	duloxetine	263
44	escitalopram	269
45	esketamine	275
46	estazolam	281
47	eszopiclone	285
48	flibanserin	289
49	flumazenil	293
50	flunitrazepam	297
51	fluoxetine	301
52	flupenthixol	307
53	fluphenazine	313
54	flurazepam	321
55	fluvoxamine	325
56	gabapentin	331
57	galantamine	337
58	guanfacine	343
59	haloperidol	347
60	hydroxyzine	355
61	iloperidone	359
62	imipramine	367
63	isocarboxazid	375
64	ketamine	383
65	lamotrigine	387
66	lemborexant	395
67	levetiracetam	399
68	levomilnacipran	403
69	lisdexamfetamine	409
70	lithium	415
71	lofepramine	421
72	lofexidine	427



loflazepate	431
lorazepam	437
loxapine	443
lumateperone	451
lurasidone	457
maprotiline	465
memantine	473
methylfolate (l)	477
methylphenidate (d)	481
methylphenidate (d,l)	487
mianserin	495
midazolam	499
milnacipran	503
mirtazapine	509
moclobemide	515
modafinil	521
molindone	527
nalmefene	533
naltrexone	537
naltrexone/bupropion	541
nefazodone	545
nortriptyline	551
olanzapine	559
oxazepam	569
oxcarbazepine	575
paliperidone	581
paroxetine	593
perospirone	601
perphenazine	607
phenelzine	613
phentermine/topiramate	619
pimavanserin	623
pimozide	627
pipothiazine	633
pitolisant	639
prazosin	643
pregabalin	647
propranolol	653
protriptyline	657
	lorazepam loxapine lumateperone lurasidone maprotiline memantine methylfolate (I) methylphenidate (d) methylphenidate (d,I) mianserin midazolam milnacipran mirtazapine moclobemide modafinil molindone nalmefene naltrexone naltrexone/bupropion nefazodone nortriptyline olanzapine oxazepam oxcarbazepine paliperidone paroxetine perospirone perphenazine phenelzine phentermine/topiramate pimavanserin pimozide pipothiazine pitolisant prazosin pregabalin propranolol



112	quazepam	663
113	quetiapine	667
114	ramelteon	677
115	reboxetine	681
116	risperidone	687
117	rivastigmine	699
118	selegiline	705
119	sertindole	715
120	sertraline	721
121	sildenafil	729
122	sodium oxybate	733
123	solriamfetol	737
124	sulpiride	741
125	suvorexant	747
126	tasimelteon	751
127	temazepam	755
128	thioridazine	759
129	thiothixene	765
130	tiagabine	771
131	tianeptine	777
132	topiramate	781
133	tranylcypromine	787
134	trazodone	793
135	triazolam	799
136	trifluoperazine	803
137	trihexyphenidyl	809
138	triiodothyronine	813
139	trimipramine	817
140	valbenazine	825
141	valproate	829
142	varenicline	837
143	venlafaxine	841
144	vilazodone	847
145	vortioxetine	853
146	zaleplon	859
147	ziprasidone	863
148	zolpidem	871
149	zonisamide	875

viii



150	zopiclone	879
151	zotepine	883
152	zuclopenthixol	889
	Index by Drug Name	895
	Index by Use	911
	Index by Class	919
	Abbreviations	923



Introduction

This Guide is intended to complement Stahl's Essential Psychopharmacology. Stahl's Essential Psychopharmacology emphasizes mechanisms of action and how psychotropic drugs work upon receptors and enzymes in the brain. This Guide gives practical information on how to use these drugs in clinical practice.

It would be impossible to include all available information about any drug in a single work, and no attempt is made here to be comprehensive. The purpose of this *Guide* is instead to integrate the art of clinical practice with the science of psychopharmacology. That means including only essential facts in order to keep things short. Unfortunately it also means excluding less critical facts as well as extraneous information, which may nevertheless be useful to the reader but would make the book too long and dilute the most important information. In deciding what to include and what to omit, the author has drawn upon common sense and 30 years of clinical experience with patients. He has also consulted with many experienced clinicians and analyzed the evidence from controlled clinical trials and regulatory filings with government agencies.

In order to meet the needs of the clinician and to facilitate future updates of this *Guide*, the opinions of readers are sincerely solicited. Feedback can be emailed to customerservice@neiglobal.com. Specifically, are the best and most essential psychotropic drugs included here? Do you find any factual errors? Are there agreements or disagreements with any of the opinions expressed here? Are there suggestions for any additional tips or pearls for future editions? Any and all suggestions and comments are welcomed.

All of the selected drugs are presented in the same format in order to facilitate rapid access to information. Specifically, each drug is broken down into five sections, each designated by a unique color background: Therapeutics, Side Effects, Dosing and Use, Special Populations, and The Art of Psychopharmacology, followed by key references.

Therapeutics covers the brand names in major countries; the class of drug; what it is commonly prescribed and approved for by the United States Food and Drug Administration (FDA); how the drug works; how long it takes to work; what to do if it works or if it doesn't work; the best augmenting combinations for partial response or treatment resistance; and the tests (if any) that are required.

Side Effects explains how the drug causes side effects; gives a list of notable, life-threatening, or dangerous side effects; gives a specific rating for weight gain or sedation; and gives advice about how to handle side effects, including best augmenting agents for side effects.

Dosing and Use gives the usual dosing range; dosage forms; how to dose and dosing tips; symptoms of overdose; long-term use; if habit forming, how to stop; pharmacokinetics; drug interactions; when not to use; and other warnings or precautions.

Special Populations gives specific information about any possible renal, hepatic, and cardiac impairments, and any precautions to be taken for treating the elderly, children, adolescents, and pregnant and breast-feeding women.

The Art of Psychopharmacology gives the author's opinions on issues such as the potential advantages and disadvantages of any one drug, the primary target symptoms, and clinical pearls to get the best out of a drug.



In addition, drugs for which switching between medications can be complicated have a special section called The Art of Switching, which includes clinical pearls and graphical representations to help guide the switching process.

There is a list of icons used in this *Guide* following this Introduction and at the back of the *Guide* are several indices. The first is an index by drug name, giving both generic names (uncapitalized) and trade names (capitalized and followed by the generic name in parentheses). The second is an index of common uses for the generic drugs included in the *Guide* and is organized by disorder/symptom. Agents that are approved by the FDA for a particular use are shown in bold. The third index is organized by drug class and lists all the agents that fall within each particular class. In addition to these indices there is a list of abbreviations.

Readers are encouraged to consult standard references¹ and comprehensive psychiatry and pharmacology textbooks for more in-depth information. They are also reminded that the Art of Psychopharmacology section is the author's opinion.

It is strongly advised that readers familiarize themselves with the standard use of these drugs before attempting any of the more exotic uses discussed, such as unusual drug combinations and doses. Reading about both drugs before augmenting one with the other is also strongly recommended. Today's psychopharmacologist should also regularly track blood pressure, weight, and body mass index for most of his or her patients. The dutiful clinician will also check out the drug interactions of noncentral nervous system (CNS) drugs with those that act in the CNS, including any prescribed by other clinicians.

Certain drugs may be for experts only, and these might include clozapine, thioridazine, pimozide, nefazodone, and monoamine oxidase (MAO) inhibitors, among others. Off-label uses not approved by the FDA and inadequately studied doses or combinations of drugs may also be for the expert only, who can weigh risks and benefits in the presence of sometimes vague and conflicting evidence. Pregnant or nursing women, or people with two or more psychiatric illnesses, substance abuse, and/or a concomitant medical illness may be suitable patients for the expert only. Controlled substances also require expertise. Use your best judgment as to your level of expertise and realize that we are all learning in this rapidly advancing field. The practice of medicine is often not so much a science as it is an art. It is important to stay within the standards of medical care for the field, and also within your personal comfort zone, while trying to help extremely ill and often difficult patients with medicines that can relieve their suffering and sometimes transform their lives.

Finally, this book is intended to be genuinely helpful for practitioners of psychopharmacology by providing them with the mixture of facts and opinions selected by the author. Ultimately, prescribing choices are the reader's responsibility. Every effort has been made in preparing this book to provide accurate and up-to-date information in accord with accepted standards and practice at the time of publication. Nevertheless, the psychopharmacology field is evolving rapidly and the author and publisher make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. Furthermore, the author and publisher disclaim any responsibility for the

¹ For example, Physician's Desk Reference and Martindale: The Complete Drug Reference.



continued currency of this information and disclaim all liability for any and all damages, including direct or consequential damages, resulting from the use of information contained in this book. Doctors recommending and patients using these drugs are strongly advised to pay careful attention to, and consult information provided by, the manufacturer.



List of icons



agomelatine



alcohol dependence treatment



alpha adrenergic blocker



alpha 2 agonist



anticonvulsant



antiparkinson/anticholinergic



benzodiazepine



benzodiazepine receptor antagonist



beta blocker



cholinesterase inhibitor



dopamine 2 antagonist



dopamine 2 partial agonist



dual orexin receptor antagonist



flibanserin



histaminic



lithium





medical food



melanocortin receptor agonist



l-methylfolate



modafinil (wake-promoter)



monoamine oxidase inhibitor



naltrexone/bupropion



nefazodone (serotonin antagonist/reuptake inhibitor)



neuroactive steroid



nicotinic partial agonist



N-methyl-D-aspartate antagonist



noradrenergic and specific serotonergic antidepressant



norepinephrine and dopamine reuptake inhibitor



phentermine/topiramate



phosphodiesterase inhibitor



pimavanserin



sedative-hypnotic

xvi





selective norepinephrine reuptake inhibitor



selective serotonin reuptake inhibitor



serotonin-dopamine antagonist



serotonin and norepinephrine reuptake inhibitor



serotonin 1A partial agonist



serotonin partial agonist reuptake inhibitor



sodium oxybate



stimulant



thyroid hormone



trazodone (serotonin antagonist/reuptake inhibitor)



tricyclic/tetracyclic antidepressant



vesicular monoamine transporter 2 inhibitor



vortioxetine



How the drug works, mechanism of action



Best augmenting agents to add for partial response or treatment resistance

xvii





Life-threatening or dangerous side effects








Weight Gain: Degrees of weight gain associated with the drug, with unusual signifying that weight gain has been reported but is not expected; not unusual signifying that weight gain occurs in a significant minority; common signifying that many experience weight gain and/or it can be significant in amount; and problematic signifying that weight gain occurs frequently, can be significant in amount, and may be a health problem in some patients







problemation





Tips for dosing based on the clinical expertise of the author



Drug interactions that may occur



Warnings and precautions regarding use of the drug



Dosing and other information specific to children and adolescents



Information regarding use of the drug during pregnancy



Clinical pearls of information based on the clinical expertise of the author



The art of switching



Suggested reading

xviii